Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998
- PMID: 39410054
- PMCID: PMC11476104
- DOI: 10.3390/cancers16193427
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998
Abstract
The authors wish to make corrections to the authorship and title of [...].
Erratum for
-
Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).Cancers (Basel). 2024 Feb 29;16(5):998. doi: 10.3390/cancers16050998. Cancers (Basel). 2024. PMID: 38473359 Free PMC article.
References
-
- Chisholm J., Mandeville H., Adams M., Minard-Collin V., Rogers T., Kelsey A., Shipley J., van Rijn R.R., de Vries I., van Ewijk R., et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Cancers. 2024;16:998. doi: 10.3390/cancers16050998. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
